Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy - Fu, Yulong; Wang, Anqi; Zhou, Jieqi; Feng, Wei; Shi, Minhua; Xu, Xiao; Zhao, Hongqing; Cai, Liming; Feng, Jian; Lv, Xuedong; Zhang, Xiaodong; Xu, Wenjing; et al. (Frontiers in Oncology, 2023)